Current reports March, 31 2021<\/p>\n\n\n\n
Legal basis: Article 17 section 1 of the Market Abuse Regulation (MAR) – confidential information.
Date: March 31, 2021, 08:51 AM<\/p>\n\n\n\n
Content of the report: <\/p>\n\n\n\n
With reference to current report No. 7\/2021 of February 10, 2021 on the selection by the National Centre for Research and Development (\u201cNCBR\u201d) for co-funding of the following project: \u201cIn vivo validation, toxicological development and implementation into clinical trials and the Company\u2019s activities of an inhalation drug candidate for the treatment of inflammatory and fibrotic lung diseases including COVID-19 complications\u201d submitted to a competition under the Smart Growth Operational Programme 2014-2020, measure 1.1\/submeasure 1.1.1., the Management Board of Celon Pharma S.A. hereby informs that on March 30, 2021 was informed that the NCRD signed a co-funding agreement for the above-mentioned project.<\/p>\n\n\n\n
Pursuant to the co-funding agreement, the total cost of the project amounts to PLN 46.9 million, and the amount of co-funding granted amounts to PLN 27.2 million. Pursuant to the co-funding agreement, the total cost of the project amounts to PLN 46.9 million, and the amount of co-funding granted amounts to PLN 27.2 million. The period of cost eligibility for the project ends on December 31, 2023.<\/p>\n\n\n\n
Detailed information on the project was provided in the aforementioned current report No. 7\/2021.<\/p>\n","protected":false},"excerpt":{"rendered":"